Comparative Pharmacology
Head-to-head clinical analysis: CHILDREN S ELIXSURE versus MEFENAMIC ACID.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CHILDREN S ELIXSURE versus MEFENAMIC ACID.
CHILDREN'S ELIXSURE vs MEFENAMIC ACID
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Acetaminophen: weakly inhibits cyclooxygenase (COX) in central nervous system, reduces prostaglandin synthesis, elevates pain threshold, and acts on hypothalamic heat-regulating center to lower body temperature. Chlorpheniramine: first-generation antihistamine; competitively antagonizes histamine at H1 receptors, reducing allergic symptoms. Dextromethorphan: noncompetitive NMDA receptor antagonist and sigma-1 agonist; suppresses cough by elevating threshold in medullary cough center. Pseudoephedrine: indirectly acting sympathomimetic; releases norepinephrine from presynaptic terminals, causing vasoconstriction and nasal decongestion.
Reversible inhibition of cyclooxygenase (COX-1 and COX-2) leading to decreased prostaglandin synthesis; exhibits both central and peripheral analgesic effects.
No established adult dose; product is specifically indicated for pediatric use only. Not recommended for adults.
500 mg orally as an initial dose, followed by 250 mg every 6 hours as needed, not to exceed 1 week.
None Documented
None Documented
Clinical Note
moderateMefenamic acid + Gatifloxacin
"Mefenamic acid may increase the neuroexcitatory activities of Gatifloxacin."
Clinical Note
moderateMefenamic acid + Rosoxacin
"Mefenamic acid may increase the neuroexcitatory activities of Rosoxacin."
Clinical Note
moderateMefenamic acid + Levofloxacin
"Mefenamic acid may increase the neuroexcitatory activities of Levofloxacin."
Clinical Note
moderateMefenamic acid + Trovafloxacin
Terminal half-life: 4–6 hours in children with normal hepatic function; prolonged to >8 hours in hepatic impairment or overdose.
Terminal half-life is 2-4 hours; prolonged in hepatic impairment and overdose.
Renal elimination: ~90% as unchanged drug and active metabolite paracetamol glucuronide/sulfate conjugates; biliary/fecal: <5%.
Primarily renal (52% as glucuronide metabolites, <6% unchanged) and fecal (20-30% via biliary elimination).
Category C
Category D/X
NSAID
NSAID
"Mefenamic acid may increase the neuroexcitatory activities of Trovafloxacin."